Description
Indication & Scope
LvMinCe® is a prescription fluorescent diagnostic agent indicated for use with the MediBeacon Transdermal GFR (TGFR) Measurement System to assess glomerular filtration rate (GFR) in adult patients.
- Mechanism: Relmapirazin is a non-radioactive fluorescent tracer that is freely filtered by the glomeruli without tubular secretion, tubular reabsorption, or metabolism. Following intravenous administration, the TGFR device continuously detects fluorescence decay through the skin to calculate measured GFR (mGFR) in real time.
- Drug class: Fluorescent diagnostic agent.
- Clinical use: Real-time assessment of glomerular filtration rate (GFR) using the TGFR Measurement System.
| Generic Name | Relmapirazin Injection |
| Brand Name | LvMinCe® |
| Ingredient | Relmapirazin |
| Dosage Form | Injection |
| Package | 7ml:130.2mg per vial |
| Conditions Treated | Assessment of glomerular filtration rate (GFR) |
| Taboos | Hypersensitivity to relmapirazin or any component of the product |
| Place of origin | China |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Store according to the approved package labeling. |
| Manufacturer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250060 |
| Date of Revision | 2025 |
| Shelf Life | Refer to the approved package labeling. |
How to use ?
Recommended Dose: The recommended dose is 7 mL (130.2 mg) administered as a single intravenous injection in conjunction with the MediBeacon Transdermal GFR (TGFR) Measurement System.
Time: Administer by intravenous injection over approximately 30–60 seconds after the TGFR sensor has been properly positioned and baseline calibration has been completed.
Instructions for use: Relmapirazin must be used exclusively with the MediBeacon TGFR Measurement System. Warm the solution to room temperature before administration and avoid extravasation, as leakage may interfere with fluorescence signal acquisition and compromise GFR measurement accuracy. The product is not intended for use as a standalone diagnostic test and should be interpreted together with the patient’s clinical findings.
Interaction: Relmapirazin is not metabolized, has minimal plasma protein binding, and is eliminated unchanged by glomerular filtration. No clinically significant drug-drug interactions have been identified.
Side effects: Adverse reactions are uncommon and generally mild, including headache, transient blood pressure fluctuations, and injection-site reactions. No serious treatment-related adverse reactions have been reported in clinical studies.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is LvMinCe® used for?
LvMinCe® is used with the MediBeacon TGFR Measurement System to assess glomerular filtration rate (GFR) in adult patients.
Is Relmapirazin a therapeutic drug?
No. It is a fluorescent diagnostic agent used for kidney function assessment.
How does Relmapirazin work?
After intravenous administration, Relmapirazin is freely filtered by the kidneys without metabolism, and the TGFR device measures fluorescence decay transdermally to calculate real-time GFR.
How is LvMinCe® administered?
It is administered as a single intravenous injection together with the TGFR Measurement System.
LvMinCe® | Relmapirazin | GFR Assessment | DengYueRX
INN: Relmapirazin
Indications: Glomerular filtration rate (GFR) assessment
Dosage Form: Injection
Strength: 7ml:130.2mg
